Cargando…

Minimum inhibitory concentrations of erythromycin and rifampin for Rhodococcus equi during the years 2007–2014

BACKGROUND: Rhodococcus equi is a gram positive, intracellular pathogen of foals worldwide. The aim of this study was to determine whether there was an increasing resistance occurring in Rhodococcus equi towards the antibiotics rifampin and erythromycin over a seven year period. The investigation wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Fenton, Caitriona S., Buckley, Thomas C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4594895/
https://www.ncbi.nlm.nih.gov/pubmed/26445669
http://dx.doi.org/10.1186/s13620-015-0051-4
_version_ 1782393495012507648
author Fenton, Caitriona S.
Buckley, Thomas C.
author_facet Fenton, Caitriona S.
Buckley, Thomas C.
author_sort Fenton, Caitriona S.
collection PubMed
description BACKGROUND: Rhodococcus equi is a gram positive, intracellular pathogen of foals worldwide. The aim of this study was to determine whether there was an increasing resistance occurring in Rhodococcus equi towards the antibiotics rifampin and erythromycin over a seven year period. The investigation was carried out with the use of E test strips (epsilometers) for rifampin and erythromycin in order to determine the Minimum Inhibitory Concentrations (MIC) values of Rhodococcus equi to these antibiotics. RESULTS: The main results of this study found that the mean MICs were higher for erythromycin than for rifampin for every year analysed apart from 2008. The results highlight that 75 % (6/8) of the mean MICs for erythromycin were above the threshold of susceptibility of 0.5 μg/ml and one of the yearly mean MICs for rifampin (2008) was above the level of ≤ 1 μg/ml. Two soil samples analysed had high MIC values of 2 μg/ml and 3 μg/ml for rifampin and erythromycin respectively. These samples can be said to have acquired resistance as they are above 1 μg/ml. CONCLUSIONS: The significance of these findings is that R. equi is already a problematic pathogen to treat and if the bacteria keeps gaining resistance to these antibiotics at rate that has been shown over the last decade, then a new form of treatment will have to be introduced. Further research into the genomics of Rhodococcus equi will, in time, shed more light on possible alternatives such as vaccines or new, more effective antimicrobials.
format Online
Article
Text
id pubmed-4594895
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45948952015-10-07 Minimum inhibitory concentrations of erythromycin and rifampin for Rhodococcus equi during the years 2007–2014 Fenton, Caitriona S. Buckley, Thomas C. Ir Vet J Research BACKGROUND: Rhodococcus equi is a gram positive, intracellular pathogen of foals worldwide. The aim of this study was to determine whether there was an increasing resistance occurring in Rhodococcus equi towards the antibiotics rifampin and erythromycin over a seven year period. The investigation was carried out with the use of E test strips (epsilometers) for rifampin and erythromycin in order to determine the Minimum Inhibitory Concentrations (MIC) values of Rhodococcus equi to these antibiotics. RESULTS: The main results of this study found that the mean MICs were higher for erythromycin than for rifampin for every year analysed apart from 2008. The results highlight that 75 % (6/8) of the mean MICs for erythromycin were above the threshold of susceptibility of 0.5 μg/ml and one of the yearly mean MICs for rifampin (2008) was above the level of ≤ 1 μg/ml. Two soil samples analysed had high MIC values of 2 μg/ml and 3 μg/ml for rifampin and erythromycin respectively. These samples can be said to have acquired resistance as they are above 1 μg/ml. CONCLUSIONS: The significance of these findings is that R. equi is already a problematic pathogen to treat and if the bacteria keeps gaining resistance to these antibiotics at rate that has been shown over the last decade, then a new form of treatment will have to be introduced. Further research into the genomics of Rhodococcus equi will, in time, shed more light on possible alternatives such as vaccines or new, more effective antimicrobials. BioMed Central 2015-10-06 /pmc/articles/PMC4594895/ /pubmed/26445669 http://dx.doi.org/10.1186/s13620-015-0051-4 Text en © Fenton and Buckley. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Fenton, Caitriona S.
Buckley, Thomas C.
Minimum inhibitory concentrations of erythromycin and rifampin for Rhodococcus equi during the years 2007–2014
title Minimum inhibitory concentrations of erythromycin and rifampin for Rhodococcus equi during the years 2007–2014
title_full Minimum inhibitory concentrations of erythromycin and rifampin for Rhodococcus equi during the years 2007–2014
title_fullStr Minimum inhibitory concentrations of erythromycin and rifampin for Rhodococcus equi during the years 2007–2014
title_full_unstemmed Minimum inhibitory concentrations of erythromycin and rifampin for Rhodococcus equi during the years 2007–2014
title_short Minimum inhibitory concentrations of erythromycin and rifampin for Rhodococcus equi during the years 2007–2014
title_sort minimum inhibitory concentrations of erythromycin and rifampin for rhodococcus equi during the years 2007–2014
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4594895/
https://www.ncbi.nlm.nih.gov/pubmed/26445669
http://dx.doi.org/10.1186/s13620-015-0051-4
work_keys_str_mv AT fentoncaitrionas minimuminhibitoryconcentrationsoferythromycinandrifampinforrhodococcusequiduringtheyears20072014
AT buckleythomasc minimuminhibitoryconcentrationsoferythromycinandrifampinforrhodococcusequiduringtheyears20072014